
AnPac Bio-Medical Science Co., Ltd. ANPC
Annual report 2022
added 12-27-2025
AnPac Bio-Medical Science Co., Ltd. Operating Income 2011-2026 | ANPC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income AnPac Bio-Medical Science Co., Ltd.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -105 M | -112 M | -94.6 M | -89.1 M | -43.6 M | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -43.6 M | -112 M | -88.8 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
-88 M | $ 8.67 | 0.35 % | $ 85.7 M | ||
|
Allakos
ALLK
|
-196 M | - | - | $ 28.6 M | ||
|
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
-51.4 M | $ 3.27 | 4.98 % | $ 279 M | ||
|
AlloVir
ALVR
|
-46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-9.95 M | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | ||
|
BeiGene, Ltd.
BGNE
|
447 M | - | 0.49 % | $ 251 B | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 99.34 | 2.73 % | $ 27.2 B | ||
|
bluebird bio
BLUE
|
-244 M | - | - | $ 546 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 4.72 | 5.23 % | $ 751 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Cabaletta Bio
CABA
|
-172 M | $ 3.23 | 0.94 % | $ 325 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
140 M | $ 21.6 | 1.12 % | $ 1.01 B | ||
|
Checkpoint Therapeutics
CKPT
|
-56.2 M | - | - | $ 169 M | ||
|
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | ||
|
Clearside Biomedical
CLSD
|
-24.8 M | - | - | $ 25.3 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-24 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
23.5 M | $ 1.54 | 4.76 % | $ 396 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 3.05 | 4.45 % | $ 5.02 M | ||
|
Aquestive Therapeutics
AQST
|
-71.1 M | $ 4.21 | 0.36 % | $ 450 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-12.2 M | $ 25.33 | 5.01 % | $ 3.22 B | ||
|
Chimerix
CMRX
|
-93.1 M | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
-77.5 M | - | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
-55.7 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
-287 M | $ 33.59 | 3.07 % | $ 2.23 B | ||
|
Autolus Therapeutics plc
AUTL
|
-271 M | $ 1.49 | 1.1 % | $ 397 M | ||
|
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | ||
|
AVROBIO
AVRO
|
10.2 M | - | 1083.1 % | $ 745 M | ||
|
CNS Pharmaceuticals
CNSP
|
-16 M | $ 2.46 | -1.99 % | $ 1.09 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
CTI BioPharma Corp.
CTIC
|
-79.8 M | - | - | $ 1.2 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M |